Eli Lilly (LLY) Growth Rates Comparisons to Major Pharmaceutical Preparations Industry, Sector, Market. Sales, Income, EPS
CSIMarket Company Name, Ticker, Suppliers, else..
 
Eli Lilly And Company  (NYSE: LLY)
 

Eli Lilly Growth Comparisons

Select each growth Category to receive further Information




Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

LLY Revenue Growth Rate Comparisons Company Industry Sector S&P 500
Y / Y Revenue Growth (Q2 MRQ) 47.67 % 12.22 % 8.91 % 10.9 %
Q / Q Revenue Growth (Q2 MRQ) 16.04 % -2.93 % -3.28 % 8.32 %
Y / Y Revenue Growth (for 12 months ending Q2 TTM) 49.58 % 9.25 % 7.98 % %
Sequential Revenue Growth (for 12 months ending Q2 TTM) 10.26 % 2.69 % 2.03 % 2.61 %
Revenue 5 Year Average Growth 21.58 % 7.41 % 8.65 % 10.59 %


LLY's Growth Comparisons in II. Quarter 2026




Strong but slowing Revenue rise by Eli Lilly of 47.67% year on year , in the second quarter 2026 to 22.97 billions, was higher than the 12.22% rise in the Major Pharmaceutical Preparations industry, and 8.91% growth in the Healthcare sector. Comparing the second quarter sales growth, both Major Pharmaceutical Preparations industry and Eli Lilly And Company outperformed 10.9% overall market increase.

Top-line improved by 16.04% from the first quarter. Looking into annual sales rise of 21.58%, and S & P 500's average yearly sales growth is 10.59% over the five years, including only Businesses with the second quarter 2026 Results. Eli Lilly grew faster than the market.

LLY Growth Rates by Company's Segments

Segment Name
Y / Y
Sequential
Net product revenue
59.06 %
-
Collaboration and other revenue
19.43 %
-
U S Sales returns rebates and discounts
200 %
-
U S
42.76 %
-
Outside U S
81.17 %
-
Cardiometabolic Health
71.16 %
-
Cardiometabolic Health U S
50.89 %
-
Cardiometabolic Health Outside U S
121.82 %
-
Mounjaro
125.46 %
-
Mounjaro U S
59.34 %
-
Mounjaro Outside U S
273.52 %
-
Zepbound
79.93 %
-
Zepbound U S
79.35 %
-
Zepbound Outside U S
271.43 %
-
Jardiance
9.86 %
-
Jardiance U S
65.16 %
-
Jardiance Outside U S
-14.61 %
-
Trulicity
-16.07 %
-
Trulicity U S
-22.18 %
-
Trulicity Outside U S
-2.15 %
-
Other cardiometabolic health
-4.23 %
-
Other cardiometabolic health U S
-16.64 %
-
Other cardiometabolic health Outside U S
12.2 %
-
Oncology
16.43 %
-
Oncology U S
17.4 %
-
Oncology Outside U S
15.3 %
-
Verzenio
12.34 %
-
Verzenio U S
7.29 %
-
Verzenio Outside U S
18.96 %
-
Other oncology
22.43 %
-
Other oncology U S
34.54 %
-
Other oncology Outside U S
11 %
-
Immunology
10.57 %
-
Immunology U S
7.09 %
-
Immunology Outside U S
14.51 %
-
Taltz
-3.81 %
-
Taltz U S
-12.58 %
-
Taltz Outside U S
10.53 %
-
Other immunology
44.17 %
-
Other immunology U S
98.04 %
-
Other immunology Outside U S
19.56 %
-
Neuroscience
40.44 %
-
Neuroscience U S
55.03 %
-
Neuroscience Outside U S
7.23 %
-
Other
-12.21 %
-
Other U S
-44 %
-
Other Outside U S
15.04 %
-
Europe
52.62 %
-
China
53.66 %
-
Japan
42.04 %
-
Rest of world
177.93 %
-
Reportable Segment
55.54 %
-
Total
55.55 %
-


Growth Rates of LLY's Income in the second quarter 2026


LLY Operating Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Operating Income Change (Q2 MRQ) - -8.88 % 4.62 % 97.6 %
Sequential Operating Income Change (Q2 MRQ) - -4.52 % 0.89 % 48.13 %
Y / Y Operating Income Growth (Q2 TTM) 20.22 % 30.63 % 30.73 % 40.67 %
Sequential Operating Income Growth (Q2 TTM) -20.99 % -2.27 % 4.82 % 20.86 %
Operating Income 5 Year Avg. Change 36.98 % 14.39 % 10.39 % 18.76 %


Income from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Income from Cont. Ops. Change (Q2 MRQ) 25.34 % -34.9 % -25.98 % 90.69 %
Sequential Income from Cont. Ops. Change (Q2 MRQ) -4.07 % -2.61 % -66.16 % 27.07 %
Y / Y Income from Cont. Ops. Change (Q2 TTM) 92.45 % 6.3 % 2.68 % 57.33 %
Sequential Income from Cont. Ops. Change (Q2 TTM) 5.68 % -10.02 % -5.02 % 18.65 %
Income from Cont. Ops. 5 Year Avg. Change 27.22 % -0.55 % 0.17 % -28.52 %

LLY Net Income Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y Net Income Growth (Q2 MRQ) 25.34 % -35.09 % -26.26 % 90.69 %
Q / Q Net Income Growth (Q2 MRQ) -4.07 % 2.87 % -0.77 % 27.07 %
Y / Y Net Income Change (Q2 TTM) 93.56 % 5.21 % 15.51 % 57.33 %
Sequential Net Income Change (Q2 TTM) 5.68 % -10.17 % -6.72 % 18.65 %
Net Income 5 Year Avg. Growth 27.22 % 14.55 % 9.21 % 22.96 %

LLY's EPS Growth Rates


EPS from Cont. Ops. Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS from Cont. Ops. Change (Q2 MRQ) 26.19 % -40.27 % -25.98 % 90.69 %
Sequential EPS from Cont. Ops. Change (Q2 MRQ) -3.87 % -7.72 % -66.16 % 27.07 %
Y / Y EPS from Cont. Ops. Change (Q2 TTM) 94.38 % - - -
Sequential EPS from Cont. Ops. Change (Q2 TTM) 5.85 % - - 4.88 %
EPS from Cont. Ops. 5 Year Avg. Growth 27.52 % -10.79 % 0.17 % -28.52 %



LLY EPS Net Growth Rates Comparisons Company Industry Sector S&P 500
Y / Y EPS Net Growth (Q2 MRQ) 26.23 % -40.45 % -26.26 % -28.52 %
Q / Q EPS Net Growth (Q2 MRQ) -3.87 % -2.53 % -0.77 % 27.07 %
Y / Y EPS Net Change (for 12 months ending Q2 TTM) - - - 7.62 %
Sequential EPS Net Change (for 12 months ending Q2 TTM) 5.86 % - - 4.93 %
EPS Net 5 Year Avg. Change 27.58 % 14.55 % 9.21 % 22.96 %



Eli Lilly showed impressive 26.23% year on year rise in the second quarter to $7.94, despite the -40.45% inMajor Pharmaceutical Preparations industry, Healthcare sector dropped -26.26%. Slow second quarter 2026 income per share, in Major Pharmaceutical Preparations industry and Healthcare sector, were portrayed in the Eli Lilly And Company results which underperformed overall market.

the bottom-line fell by -3.87% from the first quarter. Average annual income per share growth for Eli Lilly is 27.58%, while S & P 500's average yearly income per share increase is 22.96%, including only Businesses with the second quarter 2026 earnings.

LLY Cash Flow Growth Rates


Free Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Free Cash Flow Change (Q2 MRQ) 458.14 % 25.53 % 48.49 % 48.62 %
Sequential Free Cash Flow Change (Q2 MRQ) 157.96 % -42.37 % -46.96 % 34.18 %
Y / Y Free Cash Flow Change (Q2 TTM) 272.37 % 11.91 % 18.61 % 60.27 %
Sequential Free Cash Flow Change (Q2 TTM) 53.85 % 3.24 % 5.39 % 15.75 %
Free Cash Flow 5 Year Avg. Change 12.45 % 1.86 % 0.92 % 8.28 %

Net Cash Flow Growth Rates Company Industry Sector S&P 500
Y / Y Net Cash Flow Change (Q2 MRQ) - - - 339.02 %
Sequential Net Cash Flow Change (Q2 MRQ) - - - 216.68 %
Y / Y Net Cash Flow Change (Q2 TTM) 1151.81 % - - 209.43 %
Sequential Net Cash Flow Change (Q2 TTM) - - - 152.64 %
Net Cash Flow 5 Year Avg. Change 24.83 % 29.88 % 6.46 % 1.06 %

Capital Expenditures Company Industry Sector S&P 500
Y / Y Capital Expenditures Change (Q2 MRQ) 72.82 % 11.25 % 8.23 % 120.03 %
Sequential Capital Expenditures Change (Q2 MRQ) 26.1 % -25.6 % -22.09 % 36.87 %
Y / Y Capital Expenditures Change (Q2 TTM) 63.44 % 16.65 % 7.87 % 109.38 %
Sequential Capital Expenditures Change (Q2 TTM) 14.28 % 2.92 % 1.6 % 23.05 %
Capital Expenditures 5 Year Avg. Change 41.38 % 8.82 % 9.12 % 14.73 %

Note
To view Detail Information & Trends click on Individual Category.
To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table.

For explanation of terms visit: Glossary
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Y/Y Annual




Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.